The company’s rapid Zika tests utilize its proprietary OraQuick technology platform. The same platform has been used in OraSure’s rapid HIV, HCV and Ebola test kits. There are molecular Zika tests available, however, there is a short window of time in which the Zika infection can be detected before antibodies appear.
In 2015, the company developed the OraQuick rapid Ebola antigen test through a $1.8 million contract with HHS. The test could provide results within 20 minutes.
The HHS’ Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority is administering the grant.
More articles on healthcare quality
Interventions to keep chronic illness patients on their meds could save billions
Update: Dangerous bacteria detected outside of NICU at Prince George’s Hospital Center
3 wrong-site surgeries prompt changes at Phoebe Putney
